Business Context and Reporting Period
Company: Greatbatch, Inc. (Note: Metadata listed "Integer Holdings Corp," but the filing text identifies the registrant as Greatbatch, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Nine months ended October 1, 2010 (Third Quarter ended October 1, 2010)
Business Overview: Greatbatch operates two reportable segments: Greatbatch Medical (components for cardiac rhythm management, neuromodulation, vascular, and orthopaedics) and Electrochem Solutions (electrochemical cells and wireless sensors for industrial and medical applications).
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Oct 1, 2010 | Nine Months Ended Oct 1, 2010 |
|---|---|---|
| Sales | $127,490 | $400,314 |
| Gross Profit | $41,994 | $129,117 |
| Gross Margin | 32.9% | 32.3% |
| Operating Income | $13,169 | $44,482 |
| Net Income | $5,964 | $19,299 |
| Diluted EPS | $0.25 | $0.82 |
| Cash from Operations (9mo) | $72,012 | |
| Cash and Equivalents (Oct 1, 2010) | $42,996 | |
| Total Debt (Oct 1, 2010) | $239,154 | |
| Working Capital (Oct 1, 2010) | $150,630 |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 5% in Q3 2010 and 1% for the nine-month period compared to 2009. Growth was driven by the Electrochem segment (+33% in Q3) and Orthopaedics (+21% in Q3), partially offset by a slowdown in the Cardiac Rhythm Management (CRM) market (-6% in Q3).
- Profitability Improvement: Operating income turned from a loss of $23.9 million in Q3 2009 to a profit of $13.2 million in Q3 2010. This significant improvement is primarily due to the absence of a $34.5 million litigation charge recorded in Q3 2009 related to the Electrochem subsidiary.
- Expense Trends: Research, development, and engineering (RD&E) costs increased 18% in Q3 and 28% year-to-date due to strategic investments in new technologies. Selling, general, and administrative (SG&A) expenses increased slightly in Q3 due to executive death benefits but decreased year-to-date due to consolidation initiatives.
- Debt Reduction: The company utilized strong operating cash flow to repay $57.5 million of debt during the nine-month period, reducing the revolving line of credit balance from $98 million to $71 million.
Guidance, Outlook, and Risks
- 2010 Sales Outlook: Management expects full-year 2010 sales to be at the lower end of the original guidance range of $532 million to $551 million. This adjustment reflects slower growth in the CRM market and flat revenue expectations for that segment compared to the prior year.
- Market Conditions: The CEO noted that growth rates for medical markets are below initial expectations due to customer inventory adjustments and pricing pressures. These conditions are expected to persist in the foreseeable future.
- Product Development: The company received FDA clearance for the OptiSeal Valved PTFE Peelable Introducer, a new vascular product expected to generate $10–$20 million in annual revenue. Distribution agreements are expected to be finalized in Q4 2010.
- Litigation: The company is appealing a September 2009 jury verdict in the "Electrochem Litigation." A $23 million letter of credit is currently utilized to bond the appeal. A separate patent infringement action with Pressure Products was settled in August 2010.
- Regulatory Risks: Potential impacts from the Patient Protection and Affordable Care Act and proposed federal regulations regarding the transportation of lithium batteries are being monitored.
Investor Verification Checklist
- CRM Market Exposure: Verify the extent of the slowdown in the Cardiac Rhythm Management market and its impact on the largest customers (Boston Scientific, Medtronic, etc.), which collectively accounted for 60% of sales.
- Electrochem Litigation Status: Monitor the progress of the appeal regarding the $34.5 million judgment and the associated interest accruals and bonding costs.
- Debt Covenants: Confirm continued compliance with the Credit Facility covenants, specifically the adjusted EBITDA to interest expense ratio (currently 9.8:1) and total leverage ratio (currently 2.75:1).
- Adjusted vs. GAAP Metrics: Review the reconciliation of GAAP to Adjusted Operating Income and EPS, noting the exclusion of non-recurring items like litigation charges and consolidation costs to understand core operational performance.
- Foreign Currency Impact: Assess the impact of the weaker Euro on Orthopaedic sales (approx. $1.0 million reduction in Q3) and the effectiveness of hedging strategies for Mexican Peso exposures.